- Published: Monday, 08 April 2019 13:41
- Hits: 1619
- Published: Monday, 01 April 2019 11:19
- Hits: 1713
Project abstract: When the brain changes in response to stimuli it is referred as brain plasticity. When plasticity occurs, the individual nerve cells change their inner machinery, establish novel contacts (called synapses) to other nerve cells, and break others. However, all this occurs at the cellular level and we can only detect brain plasticity today if we remove the brain and study the synapses biochemically or in the microscope. This strongly limits our ability to determine if treatments are printed in the brain in real time. Most importantly, it also prevents our ability to observe changes in the brain of patients with neurological including cerebral palsy. This is very important, because such changes occur early in the disease processes. Very recent discovery of radiotracers that bind to the synaptic vesicle protein, synaptic vesicle glycoprotein 2A (SV2A) and imaging may revolutionize our ability to measure synaptic density in the living brain as an indicator of brain plasticity. We have already made significant progress in the validation of these radiotracers. In this project, using own synthesized radiotracers and validated methods, we will define the changes in binding and measure and correlate binding of these tracers in animal models of cerebral palsy as well as in fresh tissue from patients that underwent neurosurgical operation for epilepsy as an important contribution for novel diagnostics in psychiatry and neurology.
- Published: Tuesday, 22 January 2019 09:41
- Hits: 2157
- Published: Thursday, 03 January 2019 14:42
- Hits: 1679
Major grant from the Lundbeck Foundation for 5-year thematic alliance within precision medicine in epilepsy and depression
- Published: Monday, 17 December 2018 14:59
- Hits: 1714
- Published: Monday, 17 December 2018 14:07
- Hits: 1543
The defence will take place in Auditorium C, Rigshospitalet Glostrup, Valdemar Hansens Vej 5, 2600 Glostrup.
- Published: Wednesday, 03 October 2018 11:55
- Hits: 1861
- Published: Wednesday, 26 September 2018 09:12
- Hits: 1652
The aim of this proposal is to investigate basic pharmacological mechanisms and brain network effects of drugs used in classical and novel treatment of major depressive disorder (MDD). Furthermore, I will identify the effects of different 5-HT2AR agonists on functional brain connectivity which will reveal how intracellular pathways govern brain connectivity.
The classical pharmacological treatment strategy for MDD patients is the administration of SSRIs whereas hallucinogens (5-HT2AR agonists) are currently being investigated for their SSRIs whereas hallucinogens (5-HT2AR agonists) are currently being investigated for their treatment potential in various psychiatric disorders. For both SSRIs and hallucinogens, the mechanism of action is incompletely understood and for the hallucinogens this is further complicated by the fact that these 5-HT2AR agonists can differentially activate intracellular pathways - a phenomenon known as functional selectivity.
I will use hybrid positron emission tomography (PET) and magnetic resonance (MR) neuroimaging to study drug effects in vivo in humans and in non-human primates. In healthy volunteers, I will study the dose-dependent effects of citalopram administration: Changes in neuronal activation and brain circuitries will be measured with MRI and these changes will be related to the serotonin transporter occupancy measured by the PET radioligand [11C]DASB. In non-human primates, we will measure the 5-HT2AR occupancy, the hemodynamic response and changes in brain networks upon administration of two 5-HT2AR agonists: The hallucinogenic 25CN-NBOH and the non-hallucinogenic lisuride.
Identification of brain responses to these two types of anti-depressive drugs will give valuable insight into the spatial and temporal mode of action of these drugs. The outcome of this study will generate critical new information about how the involved brain circuits are affected by the pharmacological intervention and will lay the basis for a personalized medicine approach to patients with MDD.
- Published: Monday, 27 August 2018 12:04
- Hits: 1873
Liv did a great job at the defense and afterwards NRU celebrated her with a reception.
Liv replying wisely to Kelly Rohan's questions.
- Published: Thursday, 16 August 2018 14:34
- Hits: 2008
Professor Lammertsma is world-wide recognized as one of the leading figures within development of PET methodology and its applications for translational experimental medicine across a range of clinical disciplines, but particularly
for brain disorders. He has imposed internationally a culture of rigor for the quantification of regional tissue function using PET.
More Articles ...
- NRU annual report 2017
- Three travel stipends from the Lundbeck Foundation
- Two scholarships from DPS to Vibe Frøkjær
- NRU Summer Interns
- Grant from DFF to Gitte Moos Knudsen
- Olaf Paulson becomes honorary member of The Danish Neurological Society
- Large grant to Melanie Ganz from the Elsass Foundation
- Two grants to support joint research with Profs Robbins and Sahakian
- Funding from RH
- Funding from Augustinus Fonden